Cannabinoids and Parkinson's disease.

Area of Science:

• Neuroscience
• Pharmacology
• Neurodegenerative Diseases

Background:

• The cannabinoid signaling system modulates basal ganglia function, relevant to Parkinson's disease (PD).
• Cannabinoid signaling undergoes biphasic changes during PD progression: CB1 receptor downregulation in early stages and upregulation in advanced stages.
• These alterations may contribute to PD pathogenesis, including excitotoxicity, oxidative stress, and glial activation.

Purpose of the Study:

• To review the potential of cannabinoid-based medicines as therapies for Parkinson's disease.
• To explore the role of cannabinoid signaling system alterations in PD progression.
• To highlight the need for further clinical studies on cannabinoid-based treatments for PD.

Main Methods:

• Review of preclinical evidence on cannabinoid signaling in Parkinson's disease.
• Analysis of the biphasic changes in CB1 and CB2 receptors and endocannabinoids during PD progression.
• Evaluation of the neuroprotective and symptomatic treatment potential of cannabinoid agonists and antagonists.

Main Results:

• Early PD stages show CB1 receptor desensitization/downregulation, potentially worsening neurotoxicity.
• Advanced PD stages exhibit CB1 and possibly CB2 receptor upregulation, linked to motor inhibition.
• Cannabinoid agonists demonstrate neuroprotective effects by reducing excitotoxicity, oxidative stress, and glial activation.

Conclusions:

• Cannabinoid-based medicines offer promising therapeutic avenues for Parkinson's disease, targeting both motor symptoms and neurodegeneration.
• Despite strong preclinical data, clinical research on cannabinoid therapies for PD remains limited.
• Further studies are crucial to translate preclinical findings into effective clinical applications for Parkinson's disease treatment.